QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.003442v3 33/5/637    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xia, C. Q. Articles by Gan, L.-S. Search for Related Content PubMed PubMed Citation Articles by Xia, C. Q. Articles by Gan, L.-S.

EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS

Drug Metabolism and Pharmacokinetics (C.Q.X., N.L., G.M., L.-S.G.); and Slide Base Assay Team (D.Y.), Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts

The function of breast cancer resistance protein (BCRP) and its role in drug absorption, distribution, and elimination has recently been evaluated. The objective of the present study was to examine the expression, localization, and functional characteristics of BCRP in Caco-2 cells, a widely used human intestinal epithelial cell model for investigating intestinal drug absorption. The expression of BCRP in Caco-2 cells was measured by Western blotting using the antibody BXP-21. Localization of BCRP was determined by an immunofluorescence technique using both antibodies BXP-21 and BXP-34. The drug efflux function of BCRP was evaluated via the epithelial transport of methotrexate (MTX) and estrone-3-sulfate (E3S) across Caco-2 cell monolayers in the presence or absence of the BCRP inhibitors Ko143 or GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide). Results from Western blot assay indicated that Caco-2 cells in the late passage (p56) expressed a higher level of BCRP as compared with the level in the early passages (p33). The total amount of BCRP protein did not change after the cells were confluent. Immunofluorescence studies revealed the positive staining of BCRP on the apical membrane of Caco-2 cells but not on the basolateral membrane after cell confluence. MTX and E3S showed a preferential basolateral-toapical (B-to-A) transport across Caco-2 cell monolayers. Both BCRP inhibitors Ko143 and GF120918 increased the apical-to-basolateral (A-to-B) transport but decreased the B-to-A transport of MTX and E3S. Caco-2 cells may therefore be used as an in vitro model to study the transport characteristics of BCRP.

This article has been cited by other articles:

				H. Glavinas, E. Kis, A. Pal, R. Kovacs, M. Jani, E. Vagi, E. Molnar, S. Bansaghi, Z. Kele, T. Janaky, et al. ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions Drug Metab. Dispos., September 1, 2007; 35(9): 1533 - 1542. [Abstract] [Full Text] [PDF]

				P. Li, P. S. Callery, L.-S. Gan, and S. K. Balani Esterase Inhibition Attribute of Grapefruit Juice Leading to a New Drug Interaction Drug Metab. Dispos., July 1, 2007; 35(7): 1023 - 1031. [Abstract] [Full Text] [PDF]

				P. Li, P. S. Callery, L.-S. Gan, and S. K. Balani Esterase Inhibition by Grapefruit Juice Flavonoids Leading to a New Drug Interaction Drug Metab. Dispos., July 1, 2007; 35(7): 1203 - 1208. [Abstract] [Full Text] [PDF]

				B. Ebert, A. Seidel, and A. Lampen Phytochemicals Induce Breast Cancer Resistance Protein in Caco-2 Cells and Enhance the Transport of Benzo[a]pyrene-3-sulfate Toxicol. Sci., April 1, 2007; 96(2): 227 - 236. [Abstract] [Full Text] [PDF]

				C. Lu, G. T. Miwa, S. R. Prakash, L.-S. Gan, and S. K. Balani A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data Drug Metab. Dispos., January 1, 2007; 35(1): 79 - 85. [Abstract] [Full Text] [PDF]

				S. Vander Borght, L. Libbrecht, A. Katoonizadeh, J. van Pelt, D. Cassiman, F. Nevens, A. Van Lommel, B. E. Petersen, J. Fevery, P. L. Jansen, et al. Breast Cancer Resistance Protein (BCRP/ABCG2) Is Expressed by Progenitor Cells/Reactive Ductules and Hepatocytes and Its Expression Pattern Is Influenced by Disease Etiology and Species Type: Possible Functional Consequences J. Histochem. Cytochem., September 1, 2006; 54(9): 1051 - 1059. [Abstract] [Full Text] [PDF]

				G. Merino, A. I. Alvarez, M. M. Pulido, A. J. Molina, A. H. Schinkel, and J. G. Prieto BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION Drug Metab. Dispos., April 1, 2006; 34(4): 690 - 695. [Abstract] [Full Text] [PDF]

				B. Ebert, A. Seidel, and A. Lampen Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists Carcinogenesis, October 1, 2005; 26(10): 1754 - 1763. [Abstract] [Full Text] [PDF]